Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostication in MF: from CBC to cytogenetics to molecular markers.

Best practice & research. Clinical haematology - 1 Jun 2014

Zhou Amy, Oh Stephen T

Abstract excerpt

Myelofibrosis (MF) is a clonal stem cell disorder characterized by ineffective erythropoiesis and extramedullary hematopoiesis leading to progressive bone marrow failure, severe anemia, constitutional symptoms, hepatosplenomegaly, and thrombosis. MF can arise following a history of polycythemia vera (PV) or essential thrombocythemia (ET), or can present de novo as primary myelofibrosis (PMF). The disease course...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Calreticulin
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Repressor Proteins

Share to Survival Analysis

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 25189726
DOI: 10.1016/j.beha.2014.07.008

Genes

ASXL1
CALR
JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostication in MF: from CBC to cytogenetics to molecular markers.PMID 25189726Read ↗

Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Prognosis of Primary Myelofibrosis in the Genomic Era.Semantic proximity Read ↗

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and TreatmentsSemantic proximity Read ↗

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.Semantic proximity Read ↗

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.Semantic proximity Read ↗

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.Semantic proximity Read ↗

Primary Myelofibrosis: Update on Definition, Pathogenesis, and TreatmentSemantic proximity Read ↗

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

Management of Myelofibrosis: from Diagnosis to New Target Therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.